We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+33.87%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$336M
AUM Growth
+$6.15M
Cap. Flow
-$58M
Cap. Flow %
-17.27%
Top 10 Hldgs %
38.74%
Holding
96
New
16
Increased
28
Reduced
16
Closed
29

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$11.9M
2
SNY icon
Sanofi
SNY
+$10.8M
3
MDT icon
Medtronic
MDT
+$10.3M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$8.45M
5
CLDX icon
Celldex Therapeutics
CLDX
+$7.27M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$20.7M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.2M
3
SLNO
Soleno Therapeutics
SLNO
+$8.43M
4
KRYS icon
Krystal Biotech
KRYS
+$8.3M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$7.41M

Sector Composition

Rank Sector Weight
1 Healthcare 96.5%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRNX icon
76
Crinetics Pharmaceuticals
CRNX
$8.84B
– –
-220,000
Closed -$6.54M
GILD icon
77
Gilead Sciences
GILD
$162B
– –
-62,789
Closed -$4.71M
HUM icon
78
Humana
HUM
$43.7B
– –
-10,000
Closed -$4.87M
KRYS icon
79
Krystal Biotech
KRYS
$10.1B
– –
-71,531
Closed -$8.3M
NVO
80
Novo Nordisk
NVO
$208B
– –
-60,000
Closed -$5.46M
PRTA icon
81
Prothena Corp
PRTA
$425M
– –
-26,629
Closed -$1.28M
ROIV icon
82
Roivant Sciences
ROIV
$24.5B
– –
-100,000
Closed -$1.17M
RVPH
83
PUT
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
– –
-28,200
Closed -$2.75M
SGMT icon
84
Sagimet Biosciences
SGMT
$439M
– –
-100,000
Closed -$880K
SLRN
85
PUT
DELISTED
ACELYRIN
SLRN
– –
-23,000
Closed -$234K
SNDX icon
86
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-20,000
Closed -$290K
VRTX icon
87
Vertex Pharmaceuticals
VRTX
$121B
– –
-13,765
Closed -$4.79M
VYGR icon
88
Voyager Therapeutics
VYGR
$183M
– –
-103,966
Closed -$806K
XBI icon
89
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-300,000
Closed -$21.9M
CLYM
90
Climb Bio
CLYM
$681M
– –
-121,110
Closed -$319K
CBAY
91
CALL
DELISTED
Cymabay Therapeutics
CBAY
– –
-200,000
Closed -$2.98M
IMGN
92
CALL
DELISTED
Immunogen Inc
IMGN
– –
-250,000
Closed -$3.97M
IMGN
93
DELISTED
Immunogen Inc
IMGN
– –
-1,307,435
Closed -$20.7M
MRTX
94
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-200,000
Closed -$11.2M
PNT
95
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-93,700
Closed -$625K
ELOX
96
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
– –
-54,075
Closed -$260K
1 2 3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Silverarc Capital Management held 96 positions worth $336M, up 1.9% from $330M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Silverarc Capital Management withdrew a net $58M in Q4 2023, closing 29 positions and reducing 16 holdings. Its most notable exit was Immunogen Inc, an estimated $20.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 81% a quarter earlier, followed by Consumer Staples.

Against the trend, Silverarc Capital Management opened a new position in Nuvalent worth $14.2M.

  • Silverarc Capital Management's largest Q4 2023 buy was Nuvalent: 193,000 shares worth $14.2M.
  • Silverarc Capital Management added most to Akero Therapeutics in Q4 2023, an estimated $4.3M increase.
  • Silverarc Capital Management's biggest Q4 2023 reduction was Soleno Therapeutics, cutting an estimated $8.43M.
  • Silverarc Capital Management fully exited Immunogen Inc in Q4 2023, selling an estimated $20.7M.
  • Silverarc Capital Management's ten largest holdings make up 39% of its $336M portfolio in Q4 2023.
  • Silverarc Capital Management opened 16 new positions and closed 29 in Q4 2023.
  • Silverarc Capital Management's portfolio value rose 1.9% quarter-over-quarter to $336M.

Based on Silverarc Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.